Economic burden of not testing for FLT3 to treat acute myeloid leukemia.

Raymond Henderson,Dave Smart,Declan French,Jordan Clark,Kenneth Joel Bloom,Derek Hosty,Mark Lawler

Economic burden of not testing for FLT3 to treat acute myeloid leukemia.

2020

Raymond Henderson
Dave Smart
Declan French
Jordan Clark
Kenneth Joel Bloom
Derek Hosty
Mark Lawler

e13652Background: Acute myeloid leukemia (AML) is a hematologic neoplasm with poor 5-year survival (33%; US 2016), a median survival of only 4 months for relapsed/refractory cases, and in 2016, a U...

Keywords:

Myeloid leukemia
Oncology
Pathology
Internal medicine
Medicine
median survival
Neoplasm
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations